Skip to content

Regeneron Pharmaceuticals Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 30, 2026 results vs estimates

Regeneron Pharmaceuticals Inc · E.REGN.NASDAQ · United States
Use symbol E.REGN.NASDAQ in our API & Excel add-in to retrieve this data ↓
818.77
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 23.64%

Regeneron Pharmaceuticals Inc Forecast

Regeneron Pharmaceuticals Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 23.6% a year, a typical one-standard-deviation range is 791.51–846.03 over a week, 762.90–874.64 over a month and 625.22–1,012 over a year. (Signals as of 1 Nov 2026.)

Regeneron Pharmaceuticals Inc Price Chart

MacroFinance.ai

Regeneron Pharmaceuticals Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Regeneron Pharmaceuticals Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Regeneron Pharmaceuticals Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Regeneron Pharmaceuticals Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Regeneron Pharmaceuticals Inc
P/E
17.95x
Mid-range vs own history
QoQ −12.1%
YoY +1.4%
now 17.947914.85 low20.94 high
ⓘP/E As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Regeneron Pharmaceuticals Inc
P/S
5.12x
Mid-range vs own history
QoQ −10.1%
YoY −10.0%
now 5.11734.4 low6.02 high
ⓘP/S As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Regeneron Pharmaceuticals Inc
P/B
2.58x
Mid-range vs own history
QoQ −7.4%
YoY −1.4%
now 2.58112.09 low3.01 high
ⓘP/B As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Regeneron Pharmaceuticals Inc
EV/EBITDA
13.17x
Mid-range vs own history
QoQ −11.0%
YoY −0.1%
now 13.172810.38 low15.55 high
ⓘEV/EBITDA As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Regeneron Pharmaceuticals Inc
EV/Sales
4.73x
Mid-range vs own history
QoQ −10.9%
YoY −10.6%
now 4.7274 low5.61 high
ⓘEV/Sales As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Regeneron Pharmaceuticals Inc
FCF Yield
4.4%
Mid-range vs own history
QoQ +4.0%
YoY −15.9%
now 4.42543.79 low6.33 high
ⓘFCF Yield As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Regeneron Pharmaceuticals Inc
Earnings Yield
5.6%
Mid-range vs own history
QoQ +13.8%
YoY −1.4%
now 5.57174.77 low6.73 high
ⓘEarnings Yield As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Regeneron Pharmaceuticals Inc
Dividend Yield
0.4%
Mid-range vs own history
QoQ +3.5%
YoY —
now 0.4430.38 low0.57 high
ⓘDividend Yield As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Regeneron Pharmaceuticals Inc
Market Cap
$86.5B
Mid-range vs own history
QoQ −2.2%
YoY +6.7%
now 86462.11265,691 low100,898 high
ⓘMarket Cap As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Regeneron Pharmaceuticals Inc
Net Debt
-$6.6B
Mid-range vs own history
QoQ +9.8%
YoY +14.9%
now -6594.1-6,594 low-5,738 high
ⓘNet Debt As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Regeneron Pharmaceuticals Inc
Net Debt / EBITDA
-1.09x
Mid-range vs own history
QoQ +0.8%
YoY +8.3%
now -1.0876-1.09 low-1 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Regeneron Pharmaceuticals Inc
Current Ratio
3.35x
Weak vs own history
QoQ +0.5%
YoY −17.5%
now 3.35293.34 low4.13 high
ⓘCurrent Ratio As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Regeneron Pharmaceuticals Inc
Quick Ratio
2.89x
Weak vs own history
QoQ +3.9%
YoY −13.3%
now 2.88622.78 low3.39 high
ⓘQuick Ratio As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Regeneron Pharmaceuticals Inc
Interest Coverage
118.85x
Mid-range vs own history
QoQ +30.7%
YoY −3.5%
now 118.84890.94 low123.21 high
ⓘInterest Coverage As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Regeneron Pharmaceuticals Inc
Debt / Equity
0.08x
Low vs own history
QoQ +29.0%
YoY −7.5%
now 0.08080.06 low0.09 high
ⓘDebt / Equity As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Regeneron Pharmaceuticals Inc
Piotroski F-Score
7
7
QoQ +16.7%
YoY +16.7%
now 75 low7 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Regeneron Pharmaceuticals Inc
Altman Z-Score
7.19
Mid-range vs own history
QoQ −6.6%
YoY −6.5%
now 7.18826.59 low7.99 high
ⓘAltman Z-Score As of 22 Nov 2026.See Regeneron Pharmaceuticals Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  20 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Regeneron Pharmaceuticals Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Regeneron Pharmaceuticals Inc fundamentals: income statement, balance sheet & cash flow

Regeneron Pharmaceuticals Inc reported revenue of $14.34bn and net income of $4.50bn in FY2025, the year ended 31 December 2025 — revenue up 1.0% and net income up 2.1% on the prior year. Free cash flow was $4.08bn. These figures are as reported in the filings, not restated: 36 fiscal years and 147 quarters of history, back to December 1990. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$14.34bn
+1.0%
Net income
$4.50bn
+2.1%
Gross margin
85.35%
Free cash flow
$4.08bn
+11.3%
Net debt
-$412.2m
Shares short (30 Oct 2026)
2.22m
2.73 days to cover
Regeneron Pharmaceuticals Inc income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue14.3414.2013.1212.1716.07
Cost of revenue2.101.970.881.712.72
Gross profit12.2412.2312.2310.4713.35
Research & development5.855.234.443.062.62
Operating income3.583.994.054.748.95
EBITDA5.825.324.055.269.67
Interest expense0.040.060.070.060.06
Pre-tax income5.234.784.204.869.33
Income tax0.730.370.250.521.25
Net income4.504.413.954.348.08

Download Regeneron Pharmaceuticals Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.REGN.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 36 fiscal years and 147 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Regeneron Pharmaceuticals Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Regeneron Pharmaceuticals Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Regeneron Pharmaceuticals Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Regeneron Pharmaceuticals Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Regeneron Pharmaceuticals Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Regeneron Pharmaceuticals Inc (United States)

Regeneron Pharmaceuticals Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Regeneron Pharmaceuticals Inc?
Regeneron Pharmaceuticals Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Regeneron Pharmaceuticals Inc price?
The latest close is 818.77 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Regeneron Pharmaceuticals Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Regeneron Pharmaceuticals Inc?
20-day realised volatility is 23.6% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 6.8% over a month and 3.3% over a week.
What factors affect Regeneron Pharmaceuticals Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Regeneron Pharmaceuticals Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Regeneron Pharmaceuticals Inc?
58 backtested tactical asset allocation strategies trade Regeneron Pharmaceuticals Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Regeneron Pharmaceuticals Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Regeneron Pharmaceuticals Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Regeneron Pharmaceuticals Inc historical data?
In the Free historical data section of this page: the last 10 years of Regeneron Pharmaceuticals Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Regeneron Pharmaceuticals Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Regeneron Pharmaceuticals Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.REGN.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20920.69
2026-11-19922.4
2026-11-18944.567
2026-11-17956.785
2026-11-16951.43
2026-11-13954.497
2026-11-12950.222
2026-11-11958.433
2026-11-10915.127
2026-11-09919.023
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.